Good assessment Rbx.
Good early signs reading between the lines, and confirmation of a boost to efficacy through Veyonda use via this mid year presentation of data would be the confirmation of extent.
It's clear there is investment in the space, which doesn't hurt at all. Accumulation could be rewarded here.
Sitting very tight for DAART data. Any timeline on that data release?
Ann: Principal Investigator Discusses LuPIN-1 Study, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 10.0¢ | $6.181K | 58.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 42445 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 14000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
